Recessive Dystrophic Epidermolysis Bullosa
Conditions
Keywords
RDEB, COL7A1, Collagen VII
Brief summary
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is one of the most severe rare inherited skin disorders affecting children and adults. Current medical care protocols for RDEB patients are limited to palliative procedures to treat blistering and erosive lesions, wounds, and severe local and systemic complications such as fusion and contracture of the digits, skin cancer, esophageal stricture, severe anemia, infections, malnutrition and growth retardation. However, current medical treatments still cannot prevent the recurrence of the lesions arising from defective expression of type VII collagen (COL7A1), the main constituent of anchoring fibrils which form essential structures for dermal-epidermal adherence. The purpose of this study is to investigate the capacity of keratinocytes and fibroblasts to repair skin wounds in patients suffering from Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Detailed description
In the perspective of future therapeutic interventions, which could involve protein, cellular and/or gene therapy, it is essential to investigate RDEB patients with regards to their immune tolerance to type VII collagen and their capacity of their cells for tissue reconstruction.
Interventions
OTHERBlood collection
* 5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen. * 10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen * 5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria.
OTHERSkin biopsies
* A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1. * During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
7 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed molecular diagnosis of recessive dystrophic epidermolysis bullosa, established for both alleles; * Non severe generalized clinical form of RDEB; * Presence of type VII collagen on skin biopsy and/or western-blot analysis detected with a set of specific antibodies; * Presence of intact skin areas without blisters, infection or erosion; * Absence of hospitalization related to EB condition; * Patients and their parents when applicable should be able and willing to return for follow up; * Patients should be able and willing to give signed informed consent. For patients who are minor, informed consent will be signed by a legally authorized representative, as well as an assent form by the minor patient. * Ability to undergo local anesthesia.
Exclusion criteria
* Severity of disease and presence of ill-prognostic features: 1. Premature termination codon in the noncollagenous (NC1) domain of COL7A1 on both alleles; 2. Absence of detectable type VII collagen expression on skin biopsy and Western blot analysis from cultured cells; * Underlying conditions, diseases or active infections likely to increase the risk of complications or to interfere with the biological investigations: 1. History of current or previous skin cancer (Squamous cell carcinoma or other malignant skin cancer); 2. Current infectious diseases, including systemic infections and known positive HIV serology (Kaposi's sarcoma), hepatitis B and C; 3. History of current psychological or psychiatric disease; 4. Absence of an adequate familial and social support; 5. History of current or previous organ diabetes mellitus; 6. Non corrected severe anemia (Hemoglobin level: \< 8 g/ml); 7. Non corrected iron deficiency; 8. History of significant allergy to an anaesthetic procedure 9. Patient currently receiving anticoagulant or anti-aggregation treatment; 10. Participation in another clinical trial or therapy protocol for RDEB at the time of study inclusion 11. Positive pregnancy urinary test or lactating women * Not affiliated to the national social security/health service beneficiary and families with beneficiary children.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determination of the proliferative capacity of keratinocytes and fibroblasts in characterized RDEB patients | Month 23 | Populations of keratinocytes and fibroblasts isolated from punch biopsies will be analyzed for their proliferative capacity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical evaluation and scoring | Month 9 | Clinical evaluation and scoring will be assessed using The Birmingham Epidermolysis Bullosa Severity score. |
| Identification of COL7A1 mutations | Month 9 | COL7A1 mutations will be screened by direct sequencing of peripheral blood DNA using a set of primers designed to sequence the 118 COL7A1 exons and their intronic junctions. |
| Assessment of type VII collagen expression and anchoring fibrils formation in the skin | Month 9 | Punch biopsies of the patient skin will be taken and processed for cell culture (keratinocytes and fibroblasts) and for histological and ultrastructural analyses. |
Countries
France, United Kingdom
Contacts
PRINCIPAL_INVESTIGATORAlain Hovnanian, Prof
National Institut of health and medical research
Outcome results
None listed